THRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gentherm Inc (THRM) is not a strong buy at this moment for a beginner investor with a long-term focus. The stock is currently in a bearish trend with weak financial performance and mixed analyst sentiment. While there are some positive catalysts, such as new product launches and growth in automotive awards, the company faces margin pressures and declining profitability. Holding off on investment until clearer signs of recovery or stability emerge would be prudent.
The stock is in a bearish trend with key technical indicators showing weakness. The MACD is negative and contracting, RSI indicates oversold conditions at 18.12, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S2 support level of 27.323, suggesting limited downside in the short term but no clear reversal signals.
Gentherm recently partnered with KNB Communications to launch the ThermAffyx™ Patient Safety System, which has potential to drive growth in the medical device market. Additionally, the company secured $2.4 billion in new automotive business awards, indicating strong demand in its core market.
Hedge funds are aggressively selling the stock, with a significant 8556.93% increase in selling activity over the last quarter. Financial performance in Q4 2025 showed a sharp decline in net income (-80.50% YoY) and EPS (-79.59% YoY), along with margin contraction. Analysts have downgraded the stock and reduced price targets, citing margin pressures and a transition year.
In Q4 2025, revenue increased by 8.46% YoY to $382.8M, but net income dropped sharply by 80.50% YoY to $2.99M. EPS also declined by 79.59% YoY to $0.10, and gross margin fell to 23.72%, down 2.79% YoY. While revenue growth is positive, profitability metrics are deteriorating significantly.
Analyst sentiment is mixed. Freedom Capital downgraded the stock to Hold with a reduced price target of $38, citing margin pressures. Baird also lowered its price target to $36, maintaining a Neutral rating. However, Stifel initiated coverage with a Buy rating and a $41 price target, highlighting growth opportunities in automotive and adjacent markets.
